Predictive factors for anthracycline-based chemotherapy for human breast cancer-Reference-Cited by-同舟云学术

Predictive factors for anthracycline-based chemotherapy for human breast cancer

Published:2009-08-06 Issue:2 Volume:17 Page:103-109
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Miyoshi Yasuo,Kurosumi Masafumi,Kurebayashi Junichi,Matsuura Nariaki,Takahashi Masato,Tokunaga Eriko,Egawa Chiyomi,Masuda Norikazu,Kono Seishi,Morimoto Koji,Kim Seung Jin,Okishiro Masatsugu,Yanagisawa Tetsu,Ueda Satsuki,Taguchi Tetsuya,Tamaki Yasuhiro,Noguchi Shinzaburo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12282-009-0152-6.pdf

Reference36 articles.

1. Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381–7.

2. Wang JC. DNA topoisomerases. Annu Rev Biochem. 1996;65:635–92.

3. Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol. 1993;4:533–43.

4. Vincent-Salomon A, Rousseau A, Jouve M, Beuzeboc P, Sigal-Zafrani B, Freneaux P, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer. 2004;40:1502–8.

5. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–9.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MAPK Pathway Inhibition as A Rational Therapeutic Strategy for MiR-138-5p/PAQR3 Dysregulation-mediated Epirubicin Resistance in Triple-negative Breast Cancer;2021-02-28

2. Topoisomerases and cancer chemotherapy: recent advances and unanswered questions;F1000Research;2019-09-30

3. ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers;Cancers;2019-08-10

4. Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin;Cancer Management and Research;2018-11

5. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer;PLOS ONE;2016-12-15